If anyone knows the knock on first-generation cancer immunotherapy drugs, it's Matthew Krummel. Now he's working with three big drug developers to improve next-generation cancer immunotherapies.
As a graduate student in the 1990s at the University of California, Berkeley, Krummel helped to discover the first "checkpoint inhibitor" — eventually developed by Bristol-Myers Squibb Co. as Yervoy — that helps the immune system identify otherwise cloaked cancer cells.
Checkpoint inhibitors, so-called…
If anyone knows the knock on first-generation cancer immunotherapy drugs, it's Matthew Krummel. Now he's working with three big drug developers to improve next-generation cancer immunotherapies.
As a graduate student in the 1990s at the University of California, Berkeley, Krummel helped to discover the first "checkpoint inhibitor" — eventually developed by Bristol-Myers Squibb Co. as Yervoy — that helps the immune system identify otherwise cloaked cancer cells.
Checkpoint inhibitors, so-called…